Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Relationship Between Resistance to the Tyrosine Kinase Inhibitor Osimertinib and Pharmacokinetics in Non-small Cell Lung Cancer: Toward an Individualization of the Treatment (RESISTYR)

NCT05020275 is registered in ClinicalTrials.gov with Rennes University Hospital as lead sponsor.

NCT NCT05020275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05020275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Relationship Between Resistance to the Tyrosine Kinase Inhibitor Osimertinib and Pharmacokinetics in Non-small Cell Lung Cancer: Toward an Individualization of the Treatment (RESISTYR)
Lead sponsor
Rennes University Hospital
Phase
Observational
Overall status
Active, not recruiting
Start date
December 29, 2021
Completion date
March 16, 2027
Enrollment
60 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer